Investigation of demographic features, performance, comorbidity status and mortality causes among multiple myeloma patients: real-life data

References

• Kazandjian D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol. 2016;43:(6):676–681.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585–598.
   PubMed Web of Science ®Google Scholar
• Chan HSH, Chen CI, Reece DE. Current review on high-risk multiple myeloma. Curr Hematol Malig Rep. 2017;12(2):96–108.
   PubMed Web of Science ®Google Scholar
• Kleber M, Ihorst G, Terhorst M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score. Blood Cancer J. 2011;1(9):e35.
   PubMedGoogle Scholar
• Isaacs A, Fiala M, Tuchman S, et al. A comparison of three different approaches to defining frailty in older patients with multiple myeloma. J Geriatr Oncol. 2020;11(2):311–315.
   PubMed Web of Science ®Google Scholar
• Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009;23(6):1131–1138.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95(7):1150–1157.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21.
   PubMed Web of Science ®Google Scholar
• Morris EV, Edwards CM. Adipokines, adiposity, and bone marrow adipocytes: dangerous accomplices in multiple myeloma. J Cell Physiol. 2018;233(12):9159–9166.
   PubMed Web of Science ®Google Scholar
• Psaltopoulou T, Sergentanis TN, Kanellias N, et al. Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies. Int J Cancer. 2013;132(10):2413–2431.
   PubMed Web of Science ®Google Scholar
• Ugai T, Ito H, Oze I, et al. Association of BMI, smoking, and alcohol with multiple myeloma mortality in asians: a pooled analysis of more than 800,000 participants in the Asia cohort consortium. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1861–1867.
   PubMed Web of Science ®Google Scholar
• Turgutkaya A, Yavaşoğlu İ, Şahin T, et al. Multiple myeloma and frequency of synchronous and second primary malignancies. J Hematopathol. 2021. DOI:https://doi.org/10.1007/s12308-021-00453-9
   Google Scholar
• Mohammadi M, Cao Y, Glimelius I, et al. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study. BMC Cancer. 2015;15(15):850.
   PubMedGoogle Scholar
• Chari A, Mezzi K, Zhu S, et al. Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer. 2016;16(1):912.
   PubMedGoogle Scholar
• Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053–1059.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Surveillance, Epidemiology and End-results Program. Cancer Stat Facts: myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html Access date: 2021 May 04.
   Google Scholar
• Lu J, Du J, Fu WJ, et al. Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients. Zhonghua Xue Ye Xue Za Zhi. 2017;38:475–479.
   PubMedGoogle Scholar
• González-Calle V, Slack A, Keane N, et al. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018;97(8):1453–1462.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, D’Souza A, Scott E, et al. Revised international staging system is predictive and prognostic for early relapse (<24 months) after autologous transplantation for newly diagnosed multiple myeloma. Biol Blood Marrow Transplant. 2019;25:683–688.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101(9):1110–1119.
   PubMed Web of Science ®Google Scholar
• Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224–233.
   PubMed Web of Science ®Google Scholar
• Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004;4(1):94.
   PubMedGoogle Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106(8):2912–2919.
   PubMed Web of Science ®Google Scholar
• R-MCI: Myeloma Comorbidity Index for Myeloma patients. Available at: https://www.myelomacomorbidityindex.org/en_calc.html.Access date 2021 May 04
   Google Scholar
• Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910–921.
   PubMed Web of Science ®Google Scholar
• Dold SM, Möller MD, Ihorst G, et al. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica. 2021;106(3):875–880.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Ihorst G, Duque-Afonso J, et al. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020;105(5):1183–1188.
   PubMed Web of Science ®Google Scholar
• Mai EK, Haas EM, Lücke S, et al. A systematic classification of death causes in multiple myeloma. Blood Cancer J. 2018;8(3). DOI:https://doi.org/10.1038/s41408-018-0068-5
   Google Scholar
• Castañeda‐Avila MA, Ortiz‐Ortiz KJ, Torres‐Cintrón CR, et al. Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987–2013. Int J Cancer. 2020;146(1):35–43.
   PubMed Web of Science ®Google Scholar
• International Myeloma Foundation. Types of Myeloma. https://www.myeloma.org/types-of-myeloma Access date: 2021 May 04
   Google Scholar
• Majithia N, Rajkumar SV, Lacy MQ, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 2016;30(11):2208–2213.
   PubMed Web of Science ®Google Scholar